AT1 receptor blockade limits myocardial injury and upregulates AT2 receptors during reperfused myocardial infarction

Molecular and Cellular Biochemistry

Volumn 260, Issue 1, 2004, Pages 111-118

  Jugdutt, Bodh I ^a   Menon, Vijayan ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Angiotensin; Ischemia; Receptors; Reperfusion; Stunning

Indexed keywords

5 METHYL 7 PROPYL 8 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 2(3H) ONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; IRBESARTAN; UNCLASSIFIED DRUG; VALSARTAN; ANGIOTENSIN 1 RECEPTOR; BIPHENYL DERIVATIVE; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; EX VIVO STUDY; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT ATRIUM PRESSURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FILLING; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMODYNAMICS; IN VIVO STUDY; NONHUMAN; PRESSOR RESPONSE; PROTEIN EXPRESSION; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; REPERFUSION INJURY; ANIMAL; BLOOD PRESSURE; DRUG EFFECT; HEART RATE; HEART VENTRICLE; HEART VENTRICLE REMODELING; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TIME;

CANIS FAMILIARIS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DOGS; HEART RATE; HEART VENTRICLES; HEMODYNAMIC PROCESSES; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; TETRAZOLES; TIME FACTORS; VALINE; VENTRICULAR REMODELING;

EID: 4644288423     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:MCBI.0000026062.29029.d4     Document Type: Article

References (51)

1. Dahlof B, Devereux RB, Kjeldsen SE et al. for The LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359: 995-1003, 2002
2. Lindholm LH, Ibsen H, Dahlof B et al. for The LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359: 1004-1010, 2002
3. Brenner BM, Cooper ME, de Zeeuw D et al. for the RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
4. Cohn JN, Tognoni G for the Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667-1675, 2001
5. Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet 360: 752-760, 2002
6. Reimer KA, Jennings RB: The 'wavefront phenomenon' of myocardial ischemic cell death. II: Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 40: 633-644, 1979.
7. Kim CB, Braunwald E: Potential benefits of late reperfusion of infarcted myocardium. The open artery hypothesis. Circulation 88: 2426-2436, 1993
8. Jugdutt BI: Effect of reperfusion on ventricular mass, topography and function during healing of anterior infarction. Am J Physiol 272: H1205-H1211, 1997
9. Ryan TJ, Antman EM, Brooks NH et al., 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 100: 1016-1030, 1999
10. Braunwald E, Kloner RA: The stunned myocardium: Prolonged, postischemic ventricular dysfunction. Circulation 66: 1146-1149, 1982
11. Bolli R: Mechanism of myocardial stunning. Circulation 82: 723-738, 1990
12. Ford WR, Khan MI, Jugdutt BI: Effect of the novel angiotensin II type 1 receptor antagonist L-15 8,809 on acute infarct expansion and acute anterior myocardial infarction in the dog. Can J Cardiol 14: 73-80, 1998
13. Yoshiyama M, Kim S, Yamagishi H, Omura T, Tant T, Yanagi S, Toda I, Teragaki M, Akioka K, Takeuchi K, Takeda T: Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J 128: 1-6, 1994
14. Schwarz ER, Montino H, Fleischhauer J, Klues HG, vom Dahl J, Hanrath P: Angiotensin II receptor antagonist EXP3174 reduces infarct size comparable with enalaprilat and augments preconditioning in the pig heart. Cardiovasc Drugs Ther 11: 687-695, 1997
15. 2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol 32: 1787-1796, 1998
16. 1 receptor antagonist candesartan. Basic Res Cardiol 94: 208-214, 1999
17. E proteins. J Renin-Angiotensin Aldosterone Syst 1: 184-195, 2000
18. E proteins and cGMP. J Cardiovasc Pharmacol Ther 5: 301-311, 2000
19. Jugdutt BI, Xu Y, Balghith M, Menon V: Cardioprotective effects of angiotensin II type 1 receptor blockade with candesartan after reperfused myocardial infarction: Role of angiotensin II type 2 receptor. J Renin Angioten-Aldoster Syst 2: S162-S166, 2001
20. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WE, Benfield P, Carini DJ, Lee RL Wexler RR, Saye JAM, Smith RD: Angiotensin n receptors and angiotensin II receptor antagonists. Pharmacol Rev 45: 205-251, 1993
21. Jugdutt BI: Angiotensin II receptor blockers. In: M.H. Crawford (ed). 1998 Cardiology Clinics Annual of Drug Therapy, vol. 2. W.B. Saunders, Philadelphia, 1998, pp 1-17
22. Horiuchi M, Akishita M, Dzau VJ: Recent progress in Angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 33: 613-621, 1999
23. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M: Regulation and gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 95: 46-54, 1995
24. Lefroy DC, Wharton J, Crake T, Knock GA, Rutherford RAD, Susuki T, Morgan K, Palak JM, Poole-Wilson PA: Regional changes in angiotensin II receptor density after experimental myocardial infarction. J Mol Cell Cardiol 28: 429-440, 1996
25. 2 angiotensin receptor gene expression in human heart failure. Circulation 95: 1201-1206, 1997
26. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA: Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: Role of kinins and angiotensin type 2 receptors. J Clin Invest 99: 1926-1935, 1997
27. 2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 31: 349-355, 1998
28. Ping P, Takano H, Zhang J, Tang X-L, Qiu Y, Li RCX, Banerjee S, Dawn B, Balafonova Z, Bolli R: Isoform-selective activation of protein kinase C by nitric oxide in the heart of conscious rabbits. A signaling mechanism for both nitric-oxide-induced and ischemia-induced preconditioning. Circ Res 84: 587-604, 1999
29. 1 receptors. Br J Pharmacol 126: 1057-1065, 1999
30. 1 receptor. Eur J Pharmacol 319: 137-146, 1997
31. Criscione L, de Gasparo M, Buhlmayer P, Whitebread S, Ramjoue HP, Wood J: Pharmacological profile of valsartan: A potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol 110: 761-771, 1993
32. Culman J, von Heyer C, Piepenburg B, Rascher W, Unger T: Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats. Eur J Pharmacol 367: 255-265, 1999
33. Matsumura K, Jeremy RW, Schaper J, Becker LC: Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation 97: 795-804, 1998
34. Becker LC, Jeremy RW, Schaper J, Schaper W: Ultrastructural assessment of myocardial necrosis occurring during ischemia and 3-h reperfusion in the dog. Am J Physiol 277: H243-H252, 1999
35. Balghith M, Jugdutt BI: Assessment of diastolic dysfunction after acute myocardial infarction using Doppler Echocardiography. Can J Cardiol 18: 69-77, 2001
36. 2 receptor expression and blockade after acute ischemia-reperfusion in isolated working rat hearts. Am J Physiol 282: H1206-H1215, 2002
37. 2 R blockade. Hypertension 36: 506-510, 2000
38. Seyedi N, Xu XB, Nasjietti A, Hintze TH: Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 26: 164-170, 1995
39. 1 receptor blockade after reperfused myocardial infarction. J Renin-Angiotensin Aldosterone Syst 2: 134-140, 2001
40. 1 receptor blockade in reperfused myocardial infarction. In: N. Dhalla (ed). Signal Transduction and Cardiac Hypertrophy. Kluwer Academic Publishers, Boston, 2002, pp 221-236
41. Richard V, Murry CE, Reimer KA: Healing of myocardial infarcts in dogs. Effects of late reperfusion. Circulation 92: 1891-1901, 1995
42. Reinhardt D, Sigusch HH, Henße J, Tyagi SC, Körfer R, Figulla HR: Cardiac remodelling in end stage heart failure: Upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart 88: 525-530, 2002
43. Jugdutt BI, Khan MI, Jugdutt SJ, Blinston GE: Impact of left ventricular unloading after late reperfusion of canine anterior myocardial infarction on remodeling and function using isosorbide-5-mononitrate. Circulation 92: 926-934, 1995
44. Youhua Z, Shouchun X: Increased vulnerability of hypertrophied myocardium to ischemia and reperfusion injury. Relation to cardiac renin-angiotensin system. Chin Med J 108: 28-32, 1995
45. 1 receptor mRNA. Circ Res 83: 552-559, 1998
46. Chen H, Zhang YC, Li D, Phillips MI, Mehta P, Shi M, Mehta JL: Protection against myocardial dysfunction induced by global ischemia-reperfusion by antisense-oligodeoxynucleotides directed at β1-adrenoreceptor mRNA. J Pharmacol Exp Ther 294: 722-727, 2000
47. Di Napoli P, Taccardi AA, Grilli A, Spina R, Felaco M, Barsotti A, De Caterina R: Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: An ex vivo study in isolated working rat hearts. Cardiovasc Res 51: 283-293, 2001
48. Yamada T, Horiuchi M, Dzau VJ: Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 93: 156-160, 1996
49. Moudgil R, Menon V, Xu Y, Musat-Marcu S, Kumar D, Jugdutt BI: Postischemic apoptosis and functional recovery after angiotensin II type 1 receptor blockade in working rat hearts. J Hypertens 19: 1121-1129, 2001
50. Jugdutt BI, Becker LC, Hutchins GM: Early changes in collateral blood flow during myocardial infarction in conscious dogs. Am J Physiol 237: H371-H380, 1979
51. Inoue Y, Nakamura N, Inagami T: A review of mutagenesis studies of angiotensin II type 1 receptor, the three-dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism. J Hypertens 15: 703-714, 1997